Author

K. A. Dietze

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell signaling & trafficking· 2 Research Focus:cell type annotation· 2 Approach:genetic perturbation / CRISPR· 2 Assay:CITE-seq· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

D. Atanackovic· 2 shared J. M. Baker· 2 shared M. L. Olson· 2 shared S. V. Radhakrishnan· 2 shared T. Iraguha· 2 shared T. Luetkens· 2 shared A. Wang· 1 shared C. S. Lim· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

D. Atanackovic

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Restricting CAR T Cell Trafficking Expands Targetable Antigen Space

E. A. Morales, K. A. Dietze, J. M. Baker, A. Wang, S. V. Avila, F. Iglesias, S. V. Radhakrishnan, E. Vander Mause, M. L. Olson, W. Sun, E. Rosati, S. L. Chidester, T. Iraguha, X. Fan, D. Atanackovic, T. Luetkens

The paper shows that modifying integrin-mediated adhesion in CAR T cells prevents CNS targeting while maintaining anti-tumor activity against Ewing sarcoma.

bioRxiv · Feb 8, 2024 · PreprintBioengineering

Combinatorial T cell engineering eliminates on-target off-tumor toxicity of CD229 CAR T cells while maintaining anti-tumor activity.

E. R. Vander Mause, J. M. Baker, K. A. Dietze, S. V. Radhakrishnan, M. L. Olson, T. Iraguha, P. Davis, J. Panse, J. E. Marvin, M. Steinbach, D. P. Ng, C. S. Lim, D. Atanackovic, T. Luetkens

The paper engineers low-affinity CD229 CAR T cells with CJUN overexpression to reduce on-target off-tumor toxicity while preserving anti-tumor activity.

bioRxiv · Dec 6, 2021 · PreprintBioengineering